CTLA4 and esophageal squamous cell carcinoma: CTLA-4 is another well-recognized immune checkpoint, and several clinical trials has proven the effectiveness of anti-CTLA-4 monoclonal antibody as a novel immunotherapy for comprehensive treatment of ESCC.